|
|
|
|
| LEADER |
00000cam a2200000Ma 4500 |
| 001 |
SCIDIR_ocn971044806 |
| 003 |
OCoLC |
| 005 |
20231120112210.0 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
170131s2017 enk o 001 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|e pn
|c YDX
|d N$T
|d EBLCP
|d OPELS
|d IDEBK
|d OCLCQ
|d N$T
|d UAB
|d UIU
|d OCLCF
|d OTZ
|d OCLCQ
|d CASUM
|d MERER
|d OCLCQ
|d OCLCO
|d OCLCQ
|d D6H
|d U3W
|d UKMGB
|d OCLCO
|d OCLCQ
|d OCLCO
|d S2H
|d OCLCO
|d LVT
|d OCLCA
|d OCLCO
|d OCLCQ
|d SFB
|d OCLCO
|
| 015 |
|
|
|a GBB725265
|2 bnb
|
| 016 |
7 |
|
|a 018212375
|2 Uk
|
| 019 |
|
|
|a 970659016
|a 971070532
|a 971222282
|a 971346569
|a 971541001
|a 971587034
|a 1229751345
|
| 020 |
|
|
|a 9780128037980
|q (electronic bk.)
|
| 020 |
|
|
|a 0128037989
|q (electronic bk.)
|
| 020 |
|
|
|z 9780128037416
|
| 020 |
|
|
|z 0128037415
|
| 035 |
|
|
|a (OCoLC)971044806
|z (OCoLC)970659016
|z (OCoLC)971070532
|z (OCoLC)971222282
|z (OCoLC)971346569
|z (OCoLC)971541001
|z (OCoLC)971587034
|z (OCoLC)1229751345
|
| 050 |
|
4 |
|a RC280.G5
|
| 060 |
|
4 |
|a 2017 D-304
|
| 060 |
|
4 |
|a WP 145
|
| 072 |
|
7 |
|a HEA
|x 039000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 014000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 022000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 112000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 045000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 616.99/46
|2 23
|
| 245 |
0 |
0 |
|a Translational advances in gynecologic cancers /
|c edited by Michael J. Birrer, Lorenzo Ceppi.
|
| 260 |
|
|
|a London :
|b Academic Press,
|c 2017.
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 505 |
8 |
|
|a Pol and Alternative End Joining.
|
| 505 |
0 |
|
|a Front Cover; Translational Advances in Gynecologic Cancers; Copyright Page; Contents; List of Contributors; Translational Advances in Gynecologic Cancers; Introduction; I. Ovarian Cancer; 1 Origins of Epithelial Ovarian Cancer; Introduction; Embryonic Development; Serous EOC; Endometrioid EOC; Mucinous EOC; Clear Cell Carcinoma; Concluding Remarks; References; 2 Ovarian Cancer Genomics; Introduction; Low-Grade Serous Ovarian Cancer; Clear Cell Ovarian Cancer; Mucinous Ovarian Cancer; Advanced Stage Serous Ovarian Cancer; DNA Copy Number Analysis; Mutational Status; Gene Expression.
|
| 505 |
8 |
|
|a Methylation AnalysisGeneration of Clinically Relevant Signatures in OC; Gene Expression Signatures for Drug Sensitivity in OC; Recurrent Ovarian Cancer; Conclusion; List of Acronyms and Abbreviations; References; 3 Epigenetics; Introduction; Epigenetic Changes in Ovarian Cancer; Alterations in DNA Methylation; Histone Modifications in Ovarian Cancer; Expression and Function of Epigenome Modifying Enzymes in OC; DNA Methyltransferases (DNMTs); Chromatin Modifiers; Histone Methyltransferases and Demethylases in OC; Histone Acetylases and Deacetylases.
|
| 505 |
8 |
|
|a Functional Consequences of Epigenetic Alterations in OCTherapeutic Targeting of the OC Epigenome; DNMT Inhibitors; HDAC Inhibitors (HDACi); Conclusion; References; 4 Timing of Cytoreductive Surgery in the Treatment of Advanced Epithelial Ovarian Carcinoma; Introduction; History of Ovarian Cancer Surgery: Defining "Optimal"; The Quest for Complete Gross Resection: a Radical Approach; Chemotherapy Then and Now: When and How?; Primary Versus Interval Cytoreduction: Rationale; Interval Debulking Surgery: a Second Chance; Neoadjuvant Chemotherapy: Planned from the Start.
|
| 505 |
8 |
|
|a Predicting Surgical Success: Translational AdvancesIn Conclusion: What Now?; References; 5 Angiogenesis; Introduction; Angiogenesis; Vessel Sprouting Model; Tumor Angiogenesis; Growth Factor Pathways in Gynecologic Cancers; Antiangiogenic Therapies in Clinical Trials; Monoclonal Antibodies; Bevacizumab; Epithelial Ovarian Cancer; Endometrial Cancer; Cervical Cancer; Receptor Kinase Inhibitors; Fusion Peptibody; Combination Biologic Therapy; Resistance to Antiangiogenic Therapies; Biomarkers; Conclusion; Glossary; List Of Acronyms and Abbreviations; References.
|
| 505 |
8 |
|
|a 6 Homologous Recombination and BRCA Genes in Ovarian Cancer: Clinical Perspective of Novel TherapeuticsIntroduction; HR and Double-Strand DNA Break Repair; HR and Epithelial Ovarian Cancer; Hereditary Risk; HR Pathway Alterations in Epithelial Ovarian Cancer; Prognostic Impact of HRD in Ovarian Cancer; Targeting HRD in Ovarian Cancer; PARP Inhibitors: Preclinical Experience; PARP Inhibitors: Clinical Experience; BRCA-Mutated Ovarian Cancers; BRCA Wild-Type Ovarian Cancers; Mechanisms of PARP Inhibitor Resistance; Beyond PARP Inhibitors in HRD; Cell Cycle and DNA Damage Checkpoints.
|
| 500 |
|
|
|a Includes index.
|
| 588 |
0 |
|
|a Print version record.
|
| 650 |
|
0 |
|a Generative organs, Female
|x Cancer.
|
| 650 |
|
0 |
|a Human beings.
|
| 650 |
0 |
2 |
|a Female
|
| 650 |
0 |
2 |
|a Humans
|0 (DNLM)D006801
|
| 650 |
1 |
2 |
|a Genital Neoplasms, Female
|x therapy
|0 (DNLM)D005833Q000628
|
| 650 |
2 |
2 |
|a Translational Research, Biomedical
|0 (DNLM)D057170
|
| 650 |
|
6 |
|a Organes g�enitaux femelles
|x Cancer.
|0 (CaQQLa)201-0073699
|
| 650 |
|
6 |
|a �Etres humains.
|0 (CaQQLa)201-0020070
|
| 650 |
|
7 |
|a Homo sapiens (species)
|2 aat
|0 (CStmoGRI)aat300265711
|
| 650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x General.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Clinical Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Diseases.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Evidence-Based Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Internal Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a Generative organs, Female
|x Cancer
|2 fast
|0 (OCoLC)fst00939917
|
| 655 |
|
0 |
|a Electronic books.
|
| 655 |
|
4 |
|a Internet Resources.
|
| 700 |
1 |
|
|a Birrer, Michael J.
|
| 700 |
1 |
|
|a Ceppi, Lorenzo.
|
| 776 |
0 |
8 |
|i Print version:
|t Translational advances in gynecologic cancers.
|d London : Academic Press, 2017
|z 0128037415
|z 9780128037416
|w (OCoLC)959874996
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780128037416
|z Texto completo
|
